Somaxon Pharmaceuticals — Technical Presentation (June 2011)
17 slides from Somaxon Pharmaceuticals's technical presentation, Jun 15, 2011
Slide 1: Patient-Reported Symptom Improvement in Sleep Maintenance Endpoints in Adult and Elderly Patients with Insomnia
Patient-Reported Symptom Improvement in Sleep Maintenance Endpoints in Adult and Elderly Patients with Insomnia Treated with Doxepin 3 mg and 6 mg Alan Lankford, Andrew Krystal, Brian Dorsey, Roberta Rogowski, Elizabeth Ludington, H. Heith Durrence, Charles S. Davis, Thomas Roth Support for this stu
Slide 2: Introduction
Introduction The most frequent complaint of insomnia patients is sleep maintenance Defined as the inability to stay asleep throughout the night or the propensity for early morning awakenings Prevalence rates are over 70%1,2 Several well-established methods are available for assessing sleep Includes
Slide 3: Mechanism of Action and Previous Results
Mechanism of Action and Previous Results Sleep promoting effects of low dose doxepin (DXP) are likely mediated through histaminergic system DXP, at doses of 3 mg and 6 mg, is a highly potent and selective histamine receptor antagonist DXP at doses of 3 mg and 6 mg has demonstrated consistent efficac
Slide 4: Study Designs
Study Designs Subjective data from two double-blind placebo-controlled trials are reported Study A: 12-week trial of elderly patients with chronic primary insomnia N=240; DXP 1 mg and 3 mg versus placebo (PBO) Study B: 5-week trial of adult patients with chronic primary insomnia N=221; DXP 3 mg and
Slide 5: Study Design Schematics, Study A
Study Design Schematics, Study A Note. Study A is Elderly 12 week trial
Slide 6: Study Design Schematics, Study B
Study Design Schematics, Study B Note. Study B is Adult 5 week trial
Slide 7: Data Analyses
Data Analyses These post-hoc efficacy analyses were performed on ITT data set Included all randomized patients who received at least one dose of double-blind study drug sTST and sWASO were analyzed with mixed-effect model repeated measures (MMRM) approach MMRM methods are used to analyze all availab
Slide 8: Corresponding Objective Results
Corresponding Objective Results DXP 3 mg and 6 mg significantly improved PSG sleep maintenance and sleep duration in both Phase 3 trials Significant improvements in WASO and TST on Night 1 (p<0.0001) that were maintained at final time points Improvements in PSG-defined TST ranged from 25-43 minutes
Slide 9: Overall Results from MMRM Analyses
Overall Results from MMRM Analyses No interaction tests were significant None approached significance (all p-values exceeded 0.5) Results indicate no evidence that the effect of DXP 3 mg or 6 mg varied substantially over time Estimated treatment differences were significant for both sWASO and sTST a
Slide 10: Summary of MMRM Results
Summary of MMRM Results Population Measure Dose Difference vs PBO (minutes) p-value Study A sWASO DXP 3 mg -18.3 (6.49) 0.0052 Study A sTST DXP 3 mg 18.9 (7.41) 0.0114 Study B sWASO DXP 3 mg -10.2 (4.41) 0.0213 Study B sWASO DXP 6 mg -14.2 (4.41) 0.0014 Study B sTST DXP 3 mg 11.9 (5.97) 0.0469 Study
Slide 11: Mean Differences from PBO for sWASO in Study A
Mean Differences of DXP 3 mg from PBO for sWASO in Study A Minutes (LS mean) Note. sWASO data reflect improvement vs placebo, sWASO values are reduced vs placebo; error bars reflect standard error.
Slide 12: Mean Differences from PBO for sTST in Study A
Mean Differences of DXP 3 mg from PBO for sTST in Study A Minutes (LS mean) Note. Error bars reflect standard error.
Slide 13: Mean Differences from Placebo for sWASO in Study B
Mean Differences of DXP 3 mg and 6 mg from Placebo for sWASO in Study B Minutes (LS mean) Note. Data reflect the LS mean difference from placebo based on the average across two nights; sWASO data reflect improvement vs placebo, sWASO values are reduced vs placebo; error bars reflect standard error
Slide 14: Mean Differences from Placebo for sWASO in Study B
Mean Differences of DXP 3 mg and 6 mg from Placebo for sWASO in Study B Minutes (LS mean) Note. Data reflect the LS mean difference from placebo based on the average across two nights; error bars reflect standard error.
Slide 15: Summary of Adverse Events in Study B and A
Study B Study B Study B Study A Study A PBO 3 mg 6 mg PBO 3 mg OVERALL 27% 35% 32% 52% 38% Central Nervous System 14% 12% 12% 20% 11% Headache 10% 5% 0% 14% 6% Somnolence/Sedation 5% 9% 8% 5% 3% Dizziness 1% 0% 0% 2% 2% Memory Impairment 0% 0% 0% 1% 0% Gastrointestinal 4% 4% 8% 12% 6% Respiratory 3%
Slide 16: Results Summary
Results Summary In these two Phase 3 trials, DXP 3 mg and 6 mg: Demonstrated early and sustained benefit on subjective measures Estimated treatment differences significant for sWASO and sTST Treatment effects did not differ across time Had consistent sleep maintenance efficacy Subjective data parall
Slide 17: Conclusion
Conclusion DXP 3 mg and 6 mg produced significant and sustained subjective improvements Improvements observed in both sleep maintenance and sleep duration endpoints Data paralleled improvements in objective endpoints Provides further evidence of DXP 3 mg and 6 mg efficacy for treating sleep maintena
Somaxon Pharmaceuticals — Technical Presentation (June 2011) on 6ix